Fas expression in lung metastasis from osteosarcoma patients

被引:36
作者
Gordon, N
Arndt, CAS
Hawkins, DS
Dohero, DK
Inwards, CY
Munsell, MF
Stewart, J
Koshkina, NV
Kleinerman, ES
机构
[1] Univ Texas, MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[6] Mayo Clin & Mayo Fdn, Div Pediat Hematol Oncol, Rochester, MN 55905 USA
[7] Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Rochester, MN 55905 USA
[8] Childrens Hosp & Reg Med Ctr, Dept Pediat, Seattle, WA USA
关键词
APO-1/Fas; Fas ligand; osteosarcoma lung metastasis; recent chemotherapy;
D O I
10.1097/01.mph.0000188112.42576.df
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The authors' animal studies have shown that the metastatic potential of osteosarcoma (OS) cells correlates inversely with Fas expression-that is, Fas-negative cells metastasize but Fas-positive cells do not. One reason for this in the context of OS lung metastases may be that Fas-positive cells are eliminated by engagement with the Fas ligand (FasL) constitutively expressed on the surface of pneumocytes, whereas Fas-negative tumor cells are not. The purpose of this Study was to determine the status of Fas expression in OS lung metastases from patients. Specifically, archived paraffin-embedded specimens of lung metastases from 38 patients with OS were analyzed by immunohistochemistry. Lung nodules from 23 of the 38 patients (60%) were Fas negative, those from 12 patients (32%) were weakly positive, and that from only 1 patient (3%) was strongly positive. Findings in the samples from the remaining two patients (5%) could not be interpreted because of extensive necrosis. Most patients with the weakly positive tumors and the single patient with the strongly positive tumor received chemotherapy prior to lung resection. There was a significant correlation between Fas expression and the administration of preoperative salvage chemotherapy (P = 0.0013). These data indicate that loss of Fas may be one mechanism by which OS cells evade host resistance in the lung. Chemotherapy may induce regression by upregulating Fas.
引用
收藏
页码:611 / 615
页数:5
相关论文
共 33 条
[1]
Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor [J].
Armitage, JO .
BLOOD, 1998, 92 (12) :4491-4508
[2]
ARNDT C, 1996, MED PEDIATR ONCOL, V27, pA227
[3]
Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: Correlation with clinical responses [J].
Baxevanis, CN ;
Tsavaris, NB ;
Papadhimitriou, SI ;
Zarkadis, IK ;
Papadopoulos, NG ;
Bastounis, EA ;
Papamichail, M .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) :1202-1208
[4]
Bernstein Zale P, 2002, HIV Clin Trials, V3, P219
[5]
VACCINATION WITH IRRADIATED TUMOR-CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTITUMOR IMMUNITY [J].
DRANOFF, G ;
JAFFEE, E ;
LAZENBY, A ;
GOLUMBEK, P ;
LEVITSKY, H ;
BROSE, K ;
JACKSON, V ;
HAMADA, H ;
PARDOLL, D ;
MULLIGAN, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3539-3543
[6]
Gene immunotherapy in murine acute myeloid leukemia: Granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines [J].
Dunussi-Joannopoulos, K ;
Dranoff, G ;
Weinstein, HJ ;
Ferrara, JLM ;
Bierer, BE ;
Croop, JM .
BLOOD, 1998, 91 (01) :222-230
[7]
ADJUVANT CHEMOTHERAPY FOR OSTEOSARCOMA - A RANDOMIZED PROSPECTIVE TRIAL [J].
EILBER, F ;
GIULIANO, A ;
ECKARDT, J ;
PATTERSON, K ;
MOSELEY, S ;
GOODNIGHT, J .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :21-26
[8]
Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover [J].
French, LE ;
Hahne, M ;
Viard, I ;
Radlgruber, G ;
Zanone, R ;
Becker, K ;
Muller, C ;
Tschopp, J .
JOURNAL OF CELL BIOLOGY, 1996, 133 (02) :335-343
[9]
Cytotoxic drugs and the CD95 pathway [J].
Friesen, C ;
Fulda, S ;
Debatin, KM .
LEUKEMIA, 1999, 13 (11) :1854-1858
[10]
Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells [J].
Friesen, C ;
Herr, I ;
Krammer, PH ;
Debatin, KM .
NATURE MEDICINE, 1996, 2 (05) :574-577